Setmelanotide

What it is

Setmelanotide (Imcivree) is a selective MC4R agonist FDA-approved in 2020 for chronic weight management in adults and children aged 6 years and older with obesity due to specific genetic deficiencies in the leptin-melanocortin pathway: POMC deficiency, PCSK1 deficiency, LEPR deficiency, and Bardet-Biedl syndrome.

Mechanism of action

Selective MC4R activation in the hypothalamus restores function in patients with disrupted melanocortin signaling. In patients without these specific genetic conditions, setmelanotide is not effective for weight management — the targeted mechanism does not apply to common obesity.

Approved indications

Chronic weight management in patients (≥6 years) with obesity due to:

• POMC deficiency
• PCSK1 deficiency
• LEPR deficiency
• Bardet-Biedl syndrome

Genetic confirmation of one of these conditions is required for use.

Why this is out of scope at The Tide

Setmelanotide is a specialized medication for rare genetic disorders requiring confirmed genetic diagnosis. Its use is appropriately managed in genetics clinics or specialized obesity programs with experience in monogenic obesity. It is not effective and not indicated for common (non-monogenic) obesity, which represents the metabolic patient population we typically work with.

Where to learn more

Medical genetics or specialized obesity programs experienced in monogenic obesity disorders.